InSphero Competitors

Approximately 36 years before Israel declared independence, a ceremony took place on the barren slopes of Mount Carmel near the Port of Haifa, which was then occupied by the Ottoman Empire. Unknown to the Haifa community witnessing the event, this would be a milestone in history. This first cornerstone embodied an implausible vision of creating a world-class institute of scientific and technological education in the Holy Land. The story of the “Technikum” – the original German name of the Technion – is a tale of the century. The second industrial revolution created the printing presses and communications infrastructure allowing Jews scattered around the globe to organize in face of rising anti-Semitism. As Jews were often barred from technical education, the establishment of a technical school was a first priority to rebuilding a Jewish homeland. The Technion was to become a unique worldwide university that would precede, create, shape, and protect a modern state. The cornerstone laid on April 11, 1912, set in motion a century of progress responding to national and global needs. Technion – Israel Institute of Technology would grow rapidly, becoming a global pioneer in fields such as biotechnology, stem cell research, space, computer science, nanotechnology, and energy. Four Technion professors have won Nobel Prizes. As it approaches its centennial in 2025 – 100 years after the first class took place – Technion City is a thriving world center of trailblazing excellence in research and teaching for the benefit of humanity, with 18 faculties, more than 14,000 students, 135 academic programs, and 60 research institutes. Since the Technion opened its doors, more than 90,000 Technion alumni have played a huge part in creating and leading the ‘Startup Nation,’ impacting the lives of millions of people worldwide.

Moving liquids in a precise and productive way is core to the work of many laboratory professionals in the life sciences industry. Since 1965, INTEGRA has been dedicated to developing solutions for pipetting and media preparation, fulfilling the needs of our customers in research, diagnostics and quality control. It is our passion to work side by side with our customers to understand their problems and meet their needs with innovative products. In order to do this, we maintain our own sales and support organizations in the USA, Canada, China, Japan, UK, France, Germany, Austria and Switzerland, as well as a network of over 100 highly trained distribution partners worldwide. INTEGRA’s engineering and production teams in Zizers, Switzerland and Hudson, NH, USA, strive to develop and manufacture instruments and consumables of outstanding quality. In recent years, we have focused on completing our technologically advanced liquid handling product range, culminating in our ASSIST PLUS pipetting robot; a revolutionary concept that combines state of the art handheld pipettes with cutting edge robotics, freeing scientists from routine pipetting. Our latest innovation is MINI 96, the most affordable 96 channel electronic pipette on the market – fits any budget and workspace, and ready to use straight out of the box. We are proud to offer the widest product line of pipettes in the market, spanning from single channel mechanical pipettes up to 384 channel electronic benchtop platforms. Watch our corporate video to learn more: https://youtu.be/VkCiyjVlV28. Imprint: https://www.integra-biosciences.com/en/imprint

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', rebranded 'TRX BioSurgery' in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany. In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.